PL2150267T3 - Farmaceutyczna i/lub kosmetyczna kompozycja zawierająca składnik aktywny aktywujący cytochrom c - Google Patents

Farmaceutyczna i/lub kosmetyczna kompozycja zawierająca składnik aktywny aktywujący cytochrom c

Info

Publication number
PL2150267T3
PL2150267T3 PL08805497T PL08805497T PL2150267T3 PL 2150267 T3 PL2150267 T3 PL 2150267T3 PL 08805497 T PL08805497 T PL 08805497T PL 08805497 T PL08805497 T PL 08805497T PL 2150267 T3 PL2150267 T3 PL 2150267T3
Authority
PL
Poland
Prior art keywords
cytochrome
pharmaceutical
active ingredient
composition containing
cosmetic composition
Prior art date
Application number
PL08805497T
Other languages
English (en)
Inventor
Farra Claude Dal
Nouha Domloge
Jean-Marie Botto
Original Assignee
Soc Dextraction Des Principes Actifs S A Isp Vincience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soc Dextraction Des Principes Actifs S A Isp Vincience filed Critical Soc Dextraction Des Principes Actifs S A Isp Vincience
Publication of PL2150267T3 publication Critical patent/PL2150267T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08805497T 2007-04-27 2008-04-23 Farmaceutyczna i/lub kosmetyczna kompozycja zawierająca składnik aktywny aktywujący cytochrom c PL2150267T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0703057A FR2915393B1 (fr) 2007-04-27 2007-04-27 Composition pharmaceutique et/ou cosmetique contenant un principe actif activateur du cytochrome c
EP08805497A EP2150267B1 (fr) 2007-04-27 2008-04-23 Composition pharmaceutique et/ou cosmetique contenant un principe actif activateur du cytochrome c
PCT/FR2008/000578 WO2008145855A1 (fr) 2007-04-27 2008-04-23 Composition pharmaceutique et/ou cosmetique contenant un principe actif activateur du cytochrome c

Publications (1)

Publication Number Publication Date
PL2150267T3 true PL2150267T3 (pl) 2013-07-31

Family

ID=38735058

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08805497T PL2150267T3 (pl) 2007-04-27 2008-04-23 Farmaceutyczna i/lub kosmetyczna kompozycja zawierająca składnik aktywny aktywujący cytochrom c

Country Status (6)

Country Link
US (1) US8304392B2 (pl)
EP (1) EP2150267B1 (pl)
ES (1) ES2404053T3 (pl)
FR (1) FR2915393B1 (pl)
PL (1) PL2150267T3 (pl)
WO (1) WO2008145855A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948876B1 (fr) 2009-08-07 2011-11-04 Oreal Association d'un rayonnement lumineux et d'un agent de nature peptidique augmentant l'expression d'un substrat de la cytochrome c oxydase pour ameliorer notamment l'apparence de la peau et/ou du cheveu
US9375484B2 (en) * 2011-05-31 2016-06-28 Regents Of The University Of Minnesota Taxane silicate prodrugs and nanoparticles
CN117164663B (zh) * 2023-08-01 2024-05-10 青岛双元泰和药业有限公司 多肽化合物、其组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
WO2000063236A2 (en) 1999-04-16 2000-10-26 Children's Medical Center Corporation Adhesion modulatory peptides and methods for use
DE60115453T2 (de) * 2000-07-21 2006-08-24 Evotec Ag Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird
EP1324770A2 (en) 2000-09-27 2003-07-09 The UAB Research Foundation Non-replicative particulate vaccine delivery system and methods of making and using same
AU2002226030A1 (en) 2000-12-04 2002-06-18 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2004043482A1 (fr) * 2002-11-08 2004-05-27 Societe D'extraction Des Principes Actifs (Vincience) Composition cosmetique ou pharmaceutique comprenant des peptides, possedant le motif arg-gly-ser
ES2540459T3 (es) * 2004-03-12 2015-07-09 Ashland Specialties France Uso de péptidos como agente antioxidante para la preparación de una composición cosmética y/o farmacéutica
WO2007058625A1 (en) 2005-11-15 2007-05-24 Nanyang Polytechnic Toxin-antitoxin system and applications thereof
EP1864996A1 (en) 2006-06-06 2007-12-12 Helmholtz-Zentrum für Infektionsforschung GmbH Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker.

Also Published As

Publication number Publication date
EP2150267B1 (fr) 2013-03-20
US20110123466A1 (en) 2011-05-26
FR2915393A1 (fr) 2008-10-31
FR2915393B1 (fr) 2012-12-14
WO2008145855A8 (fr) 2009-07-16
ES2404053T3 (es) 2013-05-23
WO2008145855A1 (fr) 2008-12-04
EP2150267A1 (fr) 2010-02-10
US8304392B2 (en) 2012-11-06

Similar Documents

Publication Publication Date Title
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
EP2078731A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
EP2224973A4 (en) PRESERVATIVE FOR COSMETICS, BODY CARE AND PHARMACEUTICAL COMPOSITIONS
IL199397A (en) Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
GB0413730D0 (en) A pharmaceutical composition and its use
IL179795A0 (en) A pharmaceutical composition and its use
EP2220081A4 (en) GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
HK1127877A1 (en) Composition containing peptide as the active ingredient
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
IL187997A0 (en) Indane derivatives and pharmaceutical compositions containing the same
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PL2594248T3 (pl) Połączenie składników czynnych i jego zastosowanie
SI2606874T1 (sl) Novi kozmetični in/ali farmacevtski sestavki in načini njihove uporabe
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
IL188744A0 (en) High drug load formulations and dosage forms
ZA200804427B (en) Nanoparticulate active ingredient formulations
IL197107A0 (en) Pharmaceutical compositions including vitamin d and corticosteriod
IL187391A0 (en) Thiazole derivatives, their preparation and use and pharmaceutical compositions containing them
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
EP2261221A4 (en) EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS
IL183986A0 (en) Pharmaceutical compounds and compositions
HK1115315A1 (en) Tablet containing hardly soluble active ingredient
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
IL197273A0 (en) Pharmaceutical and sunscreen compositions comprising caspase-14